Elanco Animal Health Reports First Quarter 2025 Results

About this update from Elanco Animal Health Incorporated

[{"type":"text","content":"Accelerating Debt Paydown in 2025","length":33,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"First Quarter 2025 Financial Results:","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported Net Income of $67 million, Adjusted Net Income of $184 million","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $276 million, or 23.1% of Revenue","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported EPS of $0.13, Adjusted EPS of $0.37","length":44,"tagName":"p"}]},{"val":[{"type":"text","content":"Net leverage ratio of 4.4x Adjusted EBITDA","length":42,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":303,"olType":false}]},{"val":[{"type":"text","content":"Full Year 2025 Guidance:","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digits","length":232,"tagName":"p"}]},{"val":[{"type":"text","content":"Raising 2025 innovation revenue target to $660 to $740 million","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported Net Loss of $(35) to $(7) million, maintaining guidance for Adjusted EBITDA of $830 to $870 million","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported Loss Per Share of $(0.07) to $(0.01), maintaining guidance for Adjusted EPS of $0.80 to $0.86 ","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Outlook incorporates current estimate for tariff net impact of $16 to $20 million to Adjusted EBITDA and expected continued macro volatility, offset by a strong first quarter performance","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Expecting gross debt paydown of $450 to $500 million in 2025","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 year-end net leverage ratio target improved to 3.9x to 4.3x, enabled by disciplined working capital management, more favorable foreign exchange rates, a...

More updates from Elanco Animal Health Incorporated